🚀 VC round data is live in beta, check it out!
Aldeyra Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aldeyra Therapeutics and similar public comparables like Actinogen Medical, Bioton, Recce Pharmaceuticals, Laboratorios Richmond and more.
Aldeyra Therapeutics Overview
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Founded
2004
HQ
Employees
9
Website
Sectors
Financials (LTM)
EV
$41M
Aldeyra Therapeutics Financials
Aldeyra Therapeutics reported last 12-month revenue of $16M.
In the same LTM period, Aldeyra Therapeutics generated $15M in gross profit and had net loss of ($24M).
Revenue (LTM)
Aldeyra Therapeutics P&L
In the most recent fiscal year, Aldeyra Therapeutics reported revenue of — and EBITDA of ($32M).
Aldeyra Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $16M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($32M) | XXX | XXX | XXX |
| EBIT Margin | (158%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($24M) | XXX | ($34M) | XXX | XXX | XXX |
| Net Margin | (149%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aldeyra Therapeutics Stock Performance
Aldeyra Therapeutics has current market cap of $96M, and enterprise value of $41M.
Market Cap Evolution
Aldeyra Therapeutics' stock price is $1.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41M | $96M | 0.6% | XXX | XXX | XXX | $-0.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAldeyra Therapeutics Valuation Multiples
Aldeyra Therapeutics trades at 2.6x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Aldeyra Therapeutics Financial Valuation Multiples
As of April 11, 2026, Aldeyra Therapeutics has market cap of $96M and EV of $41M.
Equity research analysts estimate Aldeyra Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aldeyra Therapeutics has a P/E ratio of (4.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $96M | XXX | $96M | XXX | XXX | XXX |
| EV (current) | $41M | XXX | $41M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | (1.6x) | XXX | (1.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | — | XXX | XXX | XXX |
| P/E | (4.0x) | XXX | (2.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aldeyra Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aldeyra Therapeutics Margins & Growth Rates
Aldeyra Therapeutics' revenue in the last 12 month grew by 206%.
Aldeyra Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.9M for the same period.
Aldeyra Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 206% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (41%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 61% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 166% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aldeyra Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Actinogen Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioton | XXX | XXX | XXX | XXX | XXX | XXX |
| Recce Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Laboratorios Richmond | XXX | XXX | XXX | XXX | XXX | XXX |
| AB Science | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aldeyra Therapeutics M&A Activity
Aldeyra Therapeutics acquired XXX companies to date.
Last acquisition by Aldeyra Therapeutics was on XXXXXXXX, XXXXX. Aldeyra Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aldeyra Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAldeyra Therapeutics Investment Activity
Aldeyra Therapeutics invested in XXX companies to date.
Aldeyra Therapeutics made its latest investment on XXXXXXXX, XXXXX. Aldeyra Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aldeyra Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aldeyra Therapeutics
| When was Aldeyra Therapeutics founded? | Aldeyra Therapeutics was founded in 2004. |
| Where is Aldeyra Therapeutics headquartered? | Aldeyra Therapeutics is headquartered in United States. |
| How many employees does Aldeyra Therapeutics have? | As of today, Aldeyra Therapeutics has over 9 employees. |
| Who is the CEO of Aldeyra Therapeutics? | Aldeyra Therapeutics' CEO is Todd C. Brady. |
| Is Aldeyra Therapeutics publicly listed? | Yes, Aldeyra Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Aldeyra Therapeutics? | Aldeyra Therapeutics trades under ALDX ticker. |
| When did Aldeyra Therapeutics go public? | Aldeyra Therapeutics went public in 2014. |
| Who are competitors of Aldeyra Therapeutics? | Aldeyra Therapeutics main competitors are Actinogen Medical, Bioton, Recce Pharmaceuticals, Laboratorios Richmond. |
| What is the current market cap of Aldeyra Therapeutics? | Aldeyra Therapeutics' current market cap is $96M. |
| What is the current revenue of Aldeyra Therapeutics? | Aldeyra Therapeutics' last 12 months revenue is $16M. |
| What is the current revenue growth of Aldeyra Therapeutics? | Aldeyra Therapeutics revenue growth (NTM/LTM) is 206%. |
| What is the current EV/Revenue multiple of Aldeyra Therapeutics? | Current revenue multiple of Aldeyra Therapeutics is 2.6x. |
| Is Aldeyra Therapeutics profitable? | No, Aldeyra Therapeutics is not profitable. |
| What is the current net income of Aldeyra Therapeutics? | Aldeyra Therapeutics' last 12 months net income is ($24M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.